Would you consider using Breast Cancer Index to make decisions about extending AI therapy in patients who completed 5 years of AI, given recent data presented at SABCS 2022 about validation of BCI in IDEAL trial?
If so, which patient population would you use this in?
Answer from: Medical Oncologist at Academic Institution
Use routinely.
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I use it routinely in the 5th year of AI for LN negative cases. I heard there's difficulty in getting it covered for LN positive cases. Will review the above data. Thanks!